Greater Scrutiny for Ketek

Jamie Sheller
Attorney
(866) 735-1102 Ext 475
Posted by Jamie ShellerDecember 19, 2006 9:05 PM

Ketek is an antibiotic approved in 2004 for the treatment of pneumonia, sinusitis and bronchitis. Recently it has come under scrutiny. Due to liver problems, vision problems and possible heart rhythm distubances, the patient advocacy organization Public Citizen Health Research Group put Ketek on its "do not use" list shortly after its 2004 FDA approval. Recently, there have been reports of Ketek being linked to fatal liver problems and Senator Chuck Grassley, R-Iowa, believes that the FDA is hindering his investigation of Ketek's clinical trials. Ketek is marketed by Sanofi-Aventis, which argues that the antibiotic has a positive risk-benefit equation.

0 Comments

Have an opinion about this post? Please consider leaving a comment or subscribing to the feed to have future articles delivered to your feed reader.

Comments for this article are closed.

Subscribe to InjuryBoard Philadelphia

InjuryBoard Philadelphia RSS Feeds

Keep up with the latest updates using your favorite RSS reader

Injury Board Philadelphia is brought to you by Sheller, P.C.

Legal Assistance Center

More Info
Sheller, P.C. (866) 735-1102 Ext 475 www.sheller.com
google
Personal Injury Lawyers Serving: Statewide Pennsylvania, Philadelphia, Norristown, Cheltenham, Chester, Drexel Hill, Folsom, Havertown, King of Prussia, Levittown, Radnor, Springfield, Swarthmore, West Chester, Willow Grove
1528 Walnut Street3rd Floor, Philadelphia, Pennsylvania 19102 [ Show Map ]
Better Business Bureau Accredited Business Confidential

Your question will be referred to an attorney near you. If your question is of a legal nature, then by submitting this form you agree you are not forming a formal attorney / client relationship. Read our full privacy policy.

Looking for an InjuryBoard attorney closer to home? Click here.

Subscribe to Blog Updates

Enter your email address if you would like to receive email notifications when comments are made on this post.

Email address